Active Pharmaceutical Ingredients Market by Type, Synthesis, Potency, Product, Type of Drug, Application, Competition - Global forecast to 2031
The active pharmaceutical ingredients (API) market is expected to reach USD 199.42 billion in 2031 from USD 149.02 billion in 2026, at a CAGR of 6.0% during the forecast period. The market is prim... もっと見る
英語原文をAIを使って翻訳しています。
図表リストFIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & REGIONAL SCOPE 46.FIGURE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: YEARS CONSIDERED 47. FIGURE 3 MARKET SCENARIO 50. FIGURE 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2024–2031 51. FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2023–2026 51. FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 52. FIGURE 7 HIGH-GROWTH SEGMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2026–2031 53. FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 54. FIGURE 9 RISING DEMAND FOR INNOVATIVE, GENERIC, COMPLEX, AND BIOTECH APIS TO DRIVE MARKET GROWTH 55. FIGURE 10 INNOVATIVE APIS ACCOUNTED FOR LARGEST SHARE OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN NORTH AMERICA IN 2025 56. FIGURE 11 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING FORECAST PERIOD 57. FIGURE 12 TRADITIONAL APIS TO DOMINATE MARKET DURING FORECAST PERIOD 57. FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58. FIGURE 14 GLOBAL PHARMACEUTICAL R&D SPENDING, 2023–2030 (USD BILLION) 61. FIGURE 15 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 70. FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: VALUE CHAIN ANALYSIS 74. FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ECOSYSTEM ANALYSIS 75. FIGURE 18 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,. BY TYPE, 2025 77. FIGURE 19 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,. BY REGION, 2025 78. FIGURE 20 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80. FIGURE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT & FUNDING SCENARIO, 2025 (USD MILLION) 81. FIGURE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AI USE CASES 91. FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 101. FIGURE 24 KEY BUYING CRITERIA FOR END USERS 102. FIGURE 25 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 256. FIGURE 26 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 311. FIGURE 27 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2022–2025 (USD MILLION) 408. FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2025 409. FIGURE 29 EV/EBITDA OF KEY VENDORS 411. FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 412. FIGURE 31 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BRAND/PRODUCT COMPARISON 413. FIGURE 32 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 415. FIGURE 33 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY FOOTPRINT 416. FIGURE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 422. FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2025) 429. FIGURE 36 DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2025) 432. FIGURE 37 ASYMCHEM INC.: COMPANY SNAPSHOT (2025) 438. FIGURE 38 CIPLA: COMPANY SNAPSHOT (2025) 442. FIGURE 39 EVONIK: COMPANY SNAPSHOT (2025) 447. FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 451. FIGURE 41 SANDOZ GROUP AG: COMPANY SNAPSHOT (2025) 462. FIGURE 42 SK INC.: COMPANY SNAPSHOT (2025) 467. FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 470. FIGURE 44 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2025) 473. FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 477. FIGURE 46 AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2025) 481. FIGURE 47 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025) 484. FIGURE 48 BASF: COMPANY SNAPSHOT (2025) 487. FIGURE 49 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2025) 490. FIGURE 50 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2025) 493. FIGURE 51 EUROAPI: COMPANY SNAPSHOT (2025) 496. FIGURE 52 BACHEM: COMPANY SNAPSHOT (2025) 500. FIGURE 53 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH DESIGN 520. FIGURE 54 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BREAKDOWN OF PRIMARIES 522. FIGURE 55 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INSIGHTS FROM PRIMARIES 523. FIGURE 56 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ESTIMATION, 2025 524. FIGURE 57 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 525. FIGURE 58 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE ANALYSIS (2025) 525. FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 527. FIGURE 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CAGR PROJECTIONS 528. FIGURE 61 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DATA TRIANGULATION 529. TABLE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCLUSIONS & EXCLUSIONS 47. TABLE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 59. TABLE 3 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2024 62. TABLE 4 EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE CERTIFICATE OF SUITABILITY TO MONOGRAPHS OF EUROPEAN PHARMACOPEIA (EDQM CEP) CERTIFICATION ACTIVITY, 2024 63. TABLE 5 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,. 2023–2030 (USD BILLION) 68. TABLE 6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES 70. TABLE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ROLE IN ECOSYSTEM 75. TABLE 8 INDICATIVE PRICING OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER, 2025 (USD) 77. TABLE 9 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,. BY REGION, 2025 (USD) 78. TABLE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 79. TABLE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CASE STUDY ANALYSIS 82. TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 83. TABLE 13 KEY COMPANIES IMPLEMENTING AI 92. TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94. TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94. TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95. TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95. TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 96. TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 102. TABLE 20 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER 103. TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,. 2023–2031 (USD BILLION) 107. TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 107. TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,. 2023–2031 (USD BILLION) 108. TABLE 24 INNOVATIVE APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 109. TABLE 25 NORTH AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 109. TABLE 26 EUROPE: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110. TABLE 27 ASIA PACIFIC: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110. TABLE 28 LATIN AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 111. TABLE 29 MIDDLE EAST: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 111. TABLE 30 GCC COUNTRIES: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 111. TABLE 31 GENERIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 112. TABLE 32 NORTH AMERICA: GENERIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 113. TABLE 33 EUROPE: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 113. TABLE 34 ASIA PACIFIC: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114. TABLE 35 LATIN AMERICA: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114. TABLE 36 MIDDLE EAST: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114. TABLE 37 GCC COUNTRIES: GENERIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 115. TABLE 38 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,. 2023–2031 (USD BILLION) 117. TABLE 39 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 117. TABLE 40 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,. 2023–2031 (USD BILLION) 118. TABLE 41 TRADITIONAL APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 119. TABLE 42 NORTH AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 119. TABLE 43 EUROPE: TRADITIONAL APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 120. TABLE 44 ASIA PACIFIC: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 120. TABLE 45 LATIN AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 121. TABLE 46 MIDDLE EAST: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 121. TABLE 47 GCC COUNTRIES: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 121. TABLE 48 HIGHLY POTENT APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 122. TABLE 49 HIGHLY POTENT APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 122. TABLE 50 NORTH AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 123. TABLE 51 EUROPE: HIGHLY POTENT APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 123. TABLE 52 ASIA PACIFIC: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 124. TABLE 53 LATIN AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 124. TABLE 54 MIDDLE EAST: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 124. TABLE 55 GCC COUNTRIES: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 125. TABLE 56 SYNTHETIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 126. TABLE 57 NORTH AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 126. TABLE 58 EUROPE: SYNTHETIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 127. TABLE 59 ASIA PACIFIC: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 127. TABLE 60 LATIN AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 128. TABLE 61 MIDDLE EAST: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 128. TABLE 62 GCC COUNTRIES: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 128. TABLE 63 BIOLOGIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 129. TABLE 64 NORTH AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 130. TABLE 65 EUROPE: BIOLOGIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 130. TABLE 66 ASIA PACIFIC: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 131. TABLE 67 LATIN AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 131. TABLE 68 MIDDLE EAST: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 131. TABLE 69 GCC COUNTRIES: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 132. TABLE 70 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,. 2023–2031 (USD BILLION) 134. TABLE 71 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 134. TABLE 72 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2031 (USD BILLION) 135. TABLE 73 SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 136. TABLE 74 NORTH AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 136. TABLE 75 EUROPE: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137. TABLE 76 ASIA PACIFIC: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137. TABLE 77 LATIN AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 138. TABLE 78 MIDDLE EAST: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 138. TABLE 79 GCC COUNTRIES: SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 138. TABLE 80 SYNTHETIC APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 139. TABLE 81 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 140. TABLE 82 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 140. TABLE 83 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 141. TABLE 84 ASIA PACIFIC: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 141. TABLE 85 LATIN AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 142. TABLE 86 MIDDLE EAST: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 142. TABLE 87 GCC COUNTRIES: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 142. TABLE 88 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 143. TABLE 89 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 143. TABLE 90 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 144. TABLE 91 ASIA PACIFIC: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 144. TABLE 92 LATIN AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 145. TABLE 93 MIDDLE EAST: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 145. TABLE 94 GCC COUNTRIES: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 145. TABLE 95 BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 146. TABLE 96 NORTH AMERICA: BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 147. TABLE 97 EUROPE: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 147. TABLE 98 ASIA PACIFIC: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148. TABLE 99 LATIN AMERICA: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148. TABLE 100 MIDDLE EAST: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148. TABLE 101 GCC COUNTRIES: BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 149. TABLE 102 BIOTECH APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 149. TABLE 103 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 150. TABLE 104 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 150. TABLE 105 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 151. TABLE 106 ASIA PACIFIC: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 151. TABLE 107 LATIN AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 152. TABLE 108 MIDDLE EAST: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 152. TABLE 109 GCC COUNTRIES: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 152. TABLE 110 GENERIC BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 154. TABLE 111 NORTH AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 154. TABLE 112 EUROPE: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 155. TABLE 113 ASIA PACIFIC: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 155. TABLE 114 LATIN AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 156. TABLE 115 MIDDLE EAST: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 156. TABLE 116 GCC COUNTRIES: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 156. TABLE 117 BIOTECH APIS MARKET, BY PRODUCT, 2023–2031 (USD BILLION) 157. TABLE 118 BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,. 2023–2031 (USD BILLION) 158. TABLE 119 NORTH AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 158. TABLE 120 EUROPE: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD BILLION) 159. TABLE 121 ASIA PACIFIC: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 159. TABLE 122 LATIN AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 160. TABLE 123 MIDDLE EAST: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 160. TABLE 124 GCC COUNTRIES: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 160. TABLE 125 BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2023–2031 (USD BILLION) 161. TABLE 126 NORTH AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 161. TABLE 127 EUROPE: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,. BY COUNTRY, 2023–2031 (USD BILLION) 162. TABLE 128 ASIA PACIFIC: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,. BY COUNTRY, 2023–2031 (USD BILLION) 162. TABLE 129 LATIN AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163. TABLE 130 MIDDLE EAST: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,. BY COUNTRY, 2023–2031 (USD BILLION) 163. TABLE 131 GCC COUNTRIES: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163. TABLE 132 BIOTECH APIS MARKET FOR FUSION PROTEINS, BY REGION,. 2023–2031 (USD BILLION) 164. TABLE 133 NORTH AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 164. TABLE 134 EUROPE: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY,. 2023–2031 (USD BILLION) 165. TABLE 135 ASIA PACIFIC: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 165. TABLE 136 LATIN AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166. TABLE 137 MIDDLE EAST: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166. TABLE 138 GCC COUNTRIES: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166. TABLE 139 BIOTECH APIS MARKET FOR CYTOKINES, BY REGION, 2023–2031 (USD BILLION) 167. TABLE 140 NORTH AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 167. TABLE 141 EUROPE: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 168. TABLE 142 ASIA PACIFIC: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 168. TABLE 143 LATIN AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 169. TABLE 144 MIDDLE EAST: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 169. TABLE 145 GCC COUNTRIES: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 169. TABLE 146 BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY REGION,. 2023–2031 (USD BILLION) 170. TABLE 147 NORTH AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,. BY COUNTRY, 2023–2031 (USD BILLION) 170. TABLE 148 EUROPE: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171. TABLE 149 ASIA PACIFIC: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171. TABLE 150 LATIN AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,. BY COUNTRY, 2023–2031 (USD BILLION) 172. TABLE 151 MIDDLE EAST: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 172. TABLE 152 GCC COUNTRIES: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,. BY COUNTRY, 2023–2031 (USD BILLION) 172. TABLE 153 BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY REGION, 2023–2031 (USD BILLION) 173. TABLE 154 NORTH AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 173. TABLE 155 EUROPE: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS,. BY COUNTRY, 2023–2031 (USD BILLION) 174. TABLE 156 ASIA PACIFIC: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 174. TABLE 157 LATIN AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175. TABLE 158 MIDDLE EAST: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175. TABLE 159 GCC COUNTRIES: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175. TABLE 160 BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY REGION,. 2023–2031 (USD BILLION) 176. TABLE 161 NORTH AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 177. TABLE 162 EUROPE: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 177. TABLE 163 ASIA PACIFIC: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 178. TABLE 164 LATIN AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 178. TABLE 165 MIDDLE EAST: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 179. TABLE 166 GCC COUNTRIES: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 179. TABLE 167 BIOTECH APIS MARKET, BY EXPRESSION SYSTEM, 2023–2031 (USD BILLION) 180. TABLE 168 BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 181. TABLE 169 NORTH AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 181. TABLE 170 EUROPE: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 182. TABLE 171 ASIA PACIFIC: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 182. TABLE 172 LATIN AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183. TABLE 173 MIDDLE EAST: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183. TABLE 174 GCC COUNTRIES: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183. TABLE 175 BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 184. TABLE 176 NORTH AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 185. TABLE 177 EUROPE: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 185. TABLE 178 ASIA PACIFIC: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 186. TABLE 179 LATIN AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 186. TABLE 180 MIDDLE EAST: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 187. TABLE 181 GCC COUNTRIES: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 187. TABLE 182 BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION,. 2023–2031 (USD BILLION) 188. TABLE 183 NORTH AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 188. TABLE 184 EUROPE: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 189. TABLE 185 ASIA PACIFIC: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 189. TABLE 186 LATIN AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 190. TABLE 187 MIDDLE EAST: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 190. TABLE 188 GCC COUNTRIES: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 190. TABLE 189 BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION,. 2023–2031 (USD BILLION) 192. TABLE 190 NORTH AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 192. TABLE 191 EUROPE: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 193. TABLE 192 ASIA PACIFIC: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 193. TABLE 193 LATIN AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 194. TABLE 194 MIDDLE EAST: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 194. TABLE 195 GCC COUNTRIES: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 194. TABLE 196 BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION,. 2023–2031 (USD BILLION) 195. TABLE 197 NORTH AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 195. TABLE 198 EUROPE: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 196. TABLE 199 ASIA PACIFIC: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 196. TABLE 200 LATIN AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 197. TABLE 201 MIDDLE EAST: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 197. TABLE 202 GCC COUNTRIES: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 197. TABLE 203 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,. 2023–2031 (USD BILLION) 199. TABLE 204 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 199. TABLE 205 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2031 (USD BILLION) 200. TABLE 206 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS,. BY REGION, 2023–2031 (USD BILLION) 201. TABLE 207 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 201. TABLE 208 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202. TABLE 209 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202. TABLE 210 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203. TABLE 211 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203. TABLE 212 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203. TABLE 213 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2023–2031 (USD BILLION) 204. TABLE 214 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205. TABLE 215 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205. TABLE 216 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206. TABLE 217 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206. TABLE 218 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207. TABLE 219 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207. TABLE 220 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 209. TABLE 221 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 210. TABLE 222 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 210. TABLE 223 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2023–2031 (USD BILLION) 211. TABLE 224 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212. TABLE 225 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212. TABLE 226 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213. TABLE 227 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213. TABLE 228 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214. TABLE 229 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214. TABLE 230 LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER 215. TABLE 231 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2023–2031 (USD BILLION) 215. TABLE 232 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 216. TABLE 233 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,. BY COUNTRY, 2023–2031 (USD BILLION) 216. TABLE 234 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217. TABLE 235 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217. TABLE 236 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218. TABLE 237 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218. TABLE 238 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2023–2031 (USD BILLION) 219. TABLE 239 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 219. TABLE 240 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,. BY COUNTRY, 2023–2031 (USD BILLION) 220. TABLE 241 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 220. TABLE 242 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221. TABLE 243 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221. TABLE 244 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221. TABLE 245 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD BILLION) 222. TABLE 246 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223. TABLE 247 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223. TABLE 248 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224. TABLE 249 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224. TABLE 250 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225. TABLE 251 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225. TABLE 252 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2031 (USD BILLION) 226. TABLE 253 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 226. TABLE 254 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227. TABLE 255 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227. TABLE 256 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228. TABLE 257 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228. TABLE 258 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228. TABLE 259 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT,. BY REGION, 2023–2031 (USD BILLION) 229. TABLE 260 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230. TABLE 261 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230. TABLE 262 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231. TABLE 263 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231. TABLE 264 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232. TABLE 265 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232. TABLE 266 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2031 (USD BILLION) 233. TABLE 267 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD BILLION) 233.
SummaryThe active pharmaceutical ingredients (API) market is expected to reach USD 199.42 billion in 2031 from USD 149.02 billion in 2026, at a CAGR of 6.0% during the forecast period. The market is primarily driven by the rapid growth of oncology and rare disease pipelines, increasing development of targeted and specialty therapies, rising demand for complex and high-potency APIs (HPAPIs), and growing pharmaceutical research and development activities. The expansion of oncology and rare disease drug pipelines is increasing demand for APIs used in innovative therapies, including highly potent molecules, biologics, peptides, and other complex drug substances. These APIs support the development and manufacturing of therapies across cancer, genetic disorders, and other rare and complex diseases. In addition, the increasing adoption of precision medicine and targeted therapies is driving demand for specialized API manufacturing capabilities, particularly for complex molecules and HPAPIs. Growing investments by pharmaceutical companies in drug discovery, clinical development, and commercial manufacturing are further supporting API demand. However, market growth continues to be challenged by stringent regulatory requirements, high production and development costs, supply chain vulnerabilities, and the specialized infrastructure required for the manufacturing and handling of complex and highly potent APIs. Innovative API segment to grow at the highest CAGR during forecast period Synthetic API segment holds largest share of the market US to grow at highest CAGR during forecast period The primary interviews conducted for this report can be categorized as follows: Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Divi's Laboratories Limited (India), Sandoz Group AG (Switzerland), SK Inc. (South Korea), Merck KGaA (Germany), Dr. Reddy's Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma Limited (India), Evonik (Germany), Hikma Pharmaceuticals plc (UK), BASF (Germany), Alembic Pharmaceuticals Limited (India), Siegfried Holding AG (Switzerland), EUROAPI (France), Asymchem Inc. (China), Bachem (Switzerland), and Zhejiang Huahai Pharmaceutical Co., Ltd. (China) are some of the key companies offering products in the active pharmaceutical ingredients (API) market. Research Coverage The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the active pharmaceutical ingredients (API) market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to active pharmaceutical ingredients (API) market. This report also includes a competitive analysis of emerging startups in the active pharmaceutical ingredients (API) industry ecosystem. Key Benefits of Buying the Report The report provides insights into the following pointers: Table of Contents1 INTRODUCTION 45 2 EXECUTIVE SUMMARY 50 3 PREMIUM INSIGHTS 55 2026 VS 2031 (%) 57 4 MARKET OVERVIEW 58 5 INDUSTRY TRENDS 70 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86 7 SUSTAINABILITY & REGULATORY LANDSCAPE 94 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 106 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 116 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 133 12 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 198 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 208 14 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER 236 15 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 253 16 COMPETITIVE LANDSCAPE 406 17 COMPANY PROFILES 428 18 RESEARCH METHODOLOGY 520 19 APPENDIX 532 List of Tables/GraphsFIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & REGIONAL SCOPE 46.FIGURE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: YEARS CONSIDERED 47. FIGURE 3 MARKET SCENARIO 50. FIGURE 4 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2024–2031 51. FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2023–2026 51. FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 52. FIGURE 7 HIGH-GROWTH SEGMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2026–2031 53. FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 54. FIGURE 9 RISING DEMAND FOR INNOVATIVE, GENERIC, COMPLEX, AND BIOTECH APIS TO DRIVE MARKET GROWTH 55. FIGURE 10 INNOVATIVE APIS ACCOUNTED FOR LARGEST SHARE OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN NORTH AMERICA IN 2025 56. FIGURE 11 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING FORECAST PERIOD 57. FIGURE 12 TRADITIONAL APIS TO DOMINATE MARKET DURING FORECAST PERIOD 57. FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58. FIGURE 14 GLOBAL PHARMACEUTICAL R&D SPENDING, 2023–2030 (USD BILLION) 61. FIGURE 15 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 70. FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: VALUE CHAIN ANALYSIS 74. FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ECOSYSTEM ANALYSIS 75. FIGURE 18 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,. BY TYPE, 2025 77. FIGURE 19 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,. BY REGION, 2025 78. FIGURE 20 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80. FIGURE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT & FUNDING SCENARIO, 2025 (USD MILLION) 81. FIGURE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AI USE CASES 91. FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 101. FIGURE 24 KEY BUYING CRITERIA FOR END USERS 102. FIGURE 25 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 256. FIGURE 26 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 311. FIGURE 27 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2022–2025 (USD MILLION) 408. FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2025 409. FIGURE 29 EV/EBITDA OF KEY VENDORS 411. FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 412. FIGURE 31 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BRAND/PRODUCT COMPARISON 413. FIGURE 32 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 415. FIGURE 33 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY FOOTPRINT 416. FIGURE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 422. FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2025) 429. FIGURE 36 DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2025) 432. FIGURE 37 ASYMCHEM INC.: COMPANY SNAPSHOT (2025) 438. FIGURE 38 CIPLA: COMPANY SNAPSHOT (2025) 442. FIGURE 39 EVONIK: COMPANY SNAPSHOT (2025) 447. FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 451. FIGURE 41 SANDOZ GROUP AG: COMPANY SNAPSHOT (2025) 462. FIGURE 42 SK INC.: COMPANY SNAPSHOT (2025) 467. FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2025) 470. FIGURE 44 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2025) 473. FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 477. FIGURE 46 AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2025) 481. FIGURE 47 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025) 484. FIGURE 48 BASF: COMPANY SNAPSHOT (2025) 487. FIGURE 49 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2025) 490. FIGURE 50 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2025) 493. FIGURE 51 EUROAPI: COMPANY SNAPSHOT (2025) 496. FIGURE 52 BACHEM: COMPANY SNAPSHOT (2025) 500. FIGURE 53 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH DESIGN 520. FIGURE 54 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BREAKDOWN OF PRIMARIES 522. FIGURE 55 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INSIGHTS FROM PRIMARIES 523. FIGURE 56 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ESTIMATION, 2025 524. FIGURE 57 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 525. FIGURE 58 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE ANALYSIS (2025) 525. FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 527. FIGURE 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CAGR PROJECTIONS 528. FIGURE 61 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DATA TRIANGULATION 529. TABLE 1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCLUSIONS & EXCLUSIONS 47. TABLE 2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 59. TABLE 3 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2024 62. TABLE 4 EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE CERTIFICATE OF SUITABILITY TO MONOGRAPHS OF EUROPEAN PHARMACOPEIA (EDQM CEP) CERTIFICATION ACTIVITY, 2024 63. TABLE 5 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,. 2023–2030 (USD BILLION) 68. TABLE 6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES 70. TABLE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ROLE IN ECOSYSTEM 75. TABLE 8 INDICATIVE PRICING OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER, 2025 (USD) 77. TABLE 9 INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,. BY REGION, 2025 (USD) 78. TABLE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 79. TABLE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CASE STUDY ANALYSIS 82. TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 83. TABLE 13 KEY COMPANIES IMPLEMENTING AI 92. TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94. TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94. TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95. TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95. TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,. AND OTHER ORGANIZATIONS 96. TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 102. TABLE 20 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER 103. TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,. 2023–2031 (USD BILLION) 107. TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 107. TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,. 2023–2031 (USD BILLION) 108. TABLE 24 INNOVATIVE APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 109. TABLE 25 NORTH AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 109. TABLE 26 EUROPE: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110. TABLE 27 ASIA PACIFIC: INNOVATIVE APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 110. TABLE 28 LATIN AMERICA: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 111. TABLE 29 MIDDLE EAST: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 111. TABLE 30 GCC COUNTRIES: INNOVATIVE APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 111. TABLE 31 GENERIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 112. TABLE 32 NORTH AMERICA: GENERIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 113. TABLE 33 EUROPE: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 113. TABLE 34 ASIA PACIFIC: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114. TABLE 35 LATIN AMERICA: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114. TABLE 36 MIDDLE EAST: GENERIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 114. TABLE 37 GCC COUNTRIES: GENERIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 115. TABLE 38 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,. 2023–2031 (USD BILLION) 117. TABLE 39 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 117. TABLE 40 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,. 2023–2031 (USD BILLION) 118. TABLE 41 TRADITIONAL APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 119. TABLE 42 NORTH AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 119. TABLE 43 EUROPE: TRADITIONAL APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 120. TABLE 44 ASIA PACIFIC: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 120. TABLE 45 LATIN AMERICA: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 121. TABLE 46 MIDDLE EAST: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 121. TABLE 47 GCC COUNTRIES: TRADITIONAL APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 121. TABLE 48 HIGHLY POTENT APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 122. TABLE 49 HIGHLY POTENT APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 122. TABLE 50 NORTH AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 123. TABLE 51 EUROPE: HIGHLY POTENT APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 123. TABLE 52 ASIA PACIFIC: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 124. TABLE 53 LATIN AMERICA: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 124. TABLE 54 MIDDLE EAST: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 124. TABLE 55 GCC COUNTRIES: HIGHLY POTENT APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 125. TABLE 56 SYNTHETIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 126. TABLE 57 NORTH AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 126. TABLE 58 EUROPE: SYNTHETIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 127. TABLE 59 ASIA PACIFIC: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 127. TABLE 60 LATIN AMERICA: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 128. TABLE 61 MIDDLE EAST: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 128. TABLE 62 GCC COUNTRIES: SYNTHETIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 128. TABLE 63 BIOLOGIC HPAPIS MARKET, BY REGION, 2023–2031 (USD BILLION) 129. TABLE 64 NORTH AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 130. TABLE 65 EUROPE: BIOLOGIC HPAPIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 130. TABLE 66 ASIA PACIFIC: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 131. TABLE 67 LATIN AMERICA: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 131. TABLE 68 MIDDLE EAST: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 131. TABLE 69 GCC COUNTRIES: BIOLOGIC HPAPIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 132. TABLE 70 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,. 2023–2031 (USD BILLION) 134. TABLE 71 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 134. TABLE 72 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2031 (USD BILLION) 135. TABLE 73 SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 136. TABLE 74 NORTH AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 136. TABLE 75 EUROPE: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137. TABLE 76 ASIA PACIFIC: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 137. TABLE 77 LATIN AMERICA: SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 138. TABLE 78 MIDDLE EAST: SYNTHETIC APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 138. TABLE 79 GCC COUNTRIES: SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 138. TABLE 80 SYNTHETIC APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 139. TABLE 81 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 140. TABLE 82 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 140. TABLE 83 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 141. TABLE 84 ASIA PACIFIC: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 141. TABLE 85 LATIN AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 142. TABLE 86 MIDDLE EAST: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 142. TABLE 87 GCC COUNTRIES: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 142. TABLE 88 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 143. TABLE 89 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 143. TABLE 90 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 144. TABLE 91 ASIA PACIFIC: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 144. TABLE 92 LATIN AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 145. TABLE 93 MIDDLE EAST: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 145. TABLE 94 GCC COUNTRIES: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 145. TABLE 95 BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 146. TABLE 96 NORTH AMERICA: BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 147. TABLE 97 EUROPE: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 147. TABLE 98 ASIA PACIFIC: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148. TABLE 99 LATIN AMERICA: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148. TABLE 100 MIDDLE EAST: BIOTECH APIS MARKET, BY COUNTRY, 2023–2031 (USD BILLION) 148. TABLE 101 GCC COUNTRIES: BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 149. TABLE 102 BIOTECH APIS MARKET, BY TYPE, 2023–2031 (USD BILLION) 149. TABLE 103 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 150. TABLE 104 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 150. TABLE 105 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 151. TABLE 106 ASIA PACIFIC: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 151. TABLE 107 LATIN AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 152. TABLE 108 MIDDLE EAST: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 152. TABLE 109 GCC COUNTRIES: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 152. TABLE 110 GENERIC BIOTECH APIS MARKET, BY REGION, 2023–2031 (USD BILLION) 154. TABLE 111 NORTH AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 154. TABLE 112 EUROPE: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 155. TABLE 113 ASIA PACIFIC: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 155. TABLE 114 LATIN AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 156. TABLE 115 MIDDLE EAST: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 156. TABLE 116 GCC COUNTRIES: GENERIC BIOTECH APIS MARKET, BY COUNTRY,. 2023–2031 (USD BILLION) 156. TABLE 117 BIOTECH APIS MARKET, BY PRODUCT, 2023–2031 (USD BILLION) 157. TABLE 118 BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,. 2023–2031 (USD BILLION) 158. TABLE 119 NORTH AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 158. TABLE 120 EUROPE: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD BILLION) 159. TABLE 121 ASIA PACIFIC: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 159. TABLE 122 LATIN AMERICA: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 160. TABLE 123 MIDDLE EAST: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 160. TABLE 124 GCC COUNTRIES: BIOTECH APIS MARKET FOR MONOCLONAL ANTIBODIES,. BY COUNTRY, 2023–2031 (USD BILLION) 160. TABLE 125 BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2023–2031 (USD BILLION) 161. TABLE 126 NORTH AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 161. TABLE 127 EUROPE: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,. BY COUNTRY, 2023–2031 (USD BILLION) 162. TABLE 128 ASIA PACIFIC: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,. BY COUNTRY, 2023–2031 (USD BILLION) 162. TABLE 129 LATIN AMERICA: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163. TABLE 130 MIDDLE EAST: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS,. BY COUNTRY, 2023–2031 (USD BILLION) 163. TABLE 131 GCC COUNTRIES: BIOTECH APIS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2023–2031 (USD BILLION) 163. TABLE 132 BIOTECH APIS MARKET FOR FUSION PROTEINS, BY REGION,. 2023–2031 (USD BILLION) 164. TABLE 133 NORTH AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 164. TABLE 134 EUROPE: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY,. 2023–2031 (USD BILLION) 165. TABLE 135 ASIA PACIFIC: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 165. TABLE 136 LATIN AMERICA: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166. TABLE 137 MIDDLE EAST: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166. TABLE 138 GCC COUNTRIES: BIOTECH APIS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2031 (USD BILLION) 166. TABLE 139 BIOTECH APIS MARKET FOR CYTOKINES, BY REGION, 2023–2031 (USD BILLION) 167. TABLE 140 NORTH AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 167. TABLE 141 EUROPE: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 168. TABLE 142 ASIA PACIFIC: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 168. TABLE 143 LATIN AMERICA: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 169. TABLE 144 MIDDLE EAST: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 169. TABLE 145 GCC COUNTRIES: BIOTECH APIS MARKET FOR CYTOKINES, BY COUNTRY,. 2023–2031 (USD BILLION) 169. TABLE 146 BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY REGION,. 2023–2031 (USD BILLION) 170. TABLE 147 NORTH AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,. BY COUNTRY, 2023–2031 (USD BILLION) 170. TABLE 148 EUROPE: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171. TABLE 149 ASIA PACIFIC: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 171. TABLE 150 LATIN AMERICA: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,. BY COUNTRY, 2023–2031 (USD BILLION) 172. TABLE 151 MIDDLE EAST: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2031 (USD BILLION) 172. TABLE 152 GCC COUNTRIES: BIOTECH APIS MARKET FOR THERAPEUTIC ENZYMES,. BY COUNTRY, 2023–2031 (USD BILLION) 172. TABLE 153 BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY REGION, 2023–2031 (USD BILLION) 173. TABLE 154 NORTH AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 173. TABLE 155 EUROPE: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS,. BY COUNTRY, 2023–2031 (USD BILLION) 174. TABLE 156 ASIA PACIFIC: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 174. TABLE 157 LATIN AMERICA: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175. TABLE 158 MIDDLE EAST: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175. TABLE 159 GCC COUNTRIES: BIOTECH APIS MARKET FOR BLOOD FACTORS & ANTICOAGULANTS, BY COUNTRY, 2023–2031 (USD BILLION) 175. TABLE 160 BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY REGION,. 2023–2031 (USD BILLION) 176. TABLE 161 NORTH AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 177. TABLE 162 EUROPE: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 177. TABLE 163 ASIA PACIFIC: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2031 (USD BILLION) 178. TABLE 164 LATIN AMERICA: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 178. TABLE 165 MIDDLE EAST: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 179. TABLE 166 GCC COUNTRIES: BIOTECH APIS MARKET FOR RECOMBINANT VACCINES,. BY COUNTRY, 2023–2031 (USD BILLION) 179. TABLE 167 BIOTECH APIS MARKET, BY EXPRESSION SYSTEM, 2023–2031 (USD BILLION) 180. TABLE 168 BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 181. TABLE 169 NORTH AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 181. TABLE 170 EUROPE: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 182. TABLE 171 ASIA PACIFIC: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 182. TABLE 172 LATIN AMERICA: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183. TABLE 173 MIDDLE EAST: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183. TABLE 174 GCC COUNTRIES: BIOTECH APIS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 183. TABLE 175 BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2023–2031 (USD BILLION) 184. TABLE 176 NORTH AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 185. TABLE 177 EUROPE: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 185. TABLE 178 ASIA PACIFIC: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 186. TABLE 179 LATIN AMERICA: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 186. TABLE 180 MIDDLE EAST: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 187. TABLE 181 GCC COUNTRIES: BIOTECH APIS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 187. TABLE 182 BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION,. 2023–2031 (USD BILLION) 188. TABLE 183 NORTH AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 188. TABLE 184 EUROPE: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2031 (USD BILLION) 189. TABLE 185 ASIA PACIFIC: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 189. TABLE 186 LATIN AMERICA: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 190. TABLE 187 MIDDLE EAST: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 190. TABLE 188 GCC COUNTRIES: BIOTECH APIS MARKET FOR YEAST EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 190. TABLE 189 BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION,. 2023–2031 (USD BILLION) 192. TABLE 190 NORTH AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 192. TABLE 191 EUROPE: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 193. TABLE 192 ASIA PACIFIC: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 193. TABLE 193 LATIN AMERICA: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 194. TABLE 194 MIDDLE EAST: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 194. TABLE 195 GCC COUNTRIES: BIOTECH APIS MARKET FOR INSECT EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 194. TABLE 196 BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION,. 2023–2031 (USD BILLION) 195. TABLE 197 NORTH AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 195. TABLE 198 EUROPE: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 196. TABLE 199 ASIA PACIFIC: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 196. TABLE 200 LATIN AMERICA: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 197. TABLE 201 MIDDLE EAST: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 197. TABLE 202 GCC COUNTRIES: BIOTECH APIS MARKET FOR OTHER EXPRESSION SYSTEMS,. BY COUNTRY, 2023–2031 (USD BILLION) 197. TABLE 203 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,. 2023–2031 (USD BILLION) 199. TABLE 204 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 199. TABLE 205 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2031 (USD BILLION) 200. TABLE 206 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS,. BY REGION, 2023–2031 (USD BILLION) 201. TABLE 207 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 201. TABLE 208 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202. TABLE 209 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 202. TABLE 210 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203. TABLE 211 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203. TABLE 212 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 203. TABLE 213 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2023–2031 (USD BILLION) 204. TABLE 214 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205. TABLE 215 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 205. TABLE 216 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206. TABLE 217 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 206. TABLE 218 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207. TABLE 219 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2031 (USD BILLION) 207. TABLE 220 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 209. TABLE 221 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2023–2031 (USD BILLION) 210. TABLE 222 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2031 (USD BILLION) 210. TABLE 223 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2023–2031 (USD BILLION) 211. TABLE 224 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212. TABLE 225 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 212. TABLE 226 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213. TABLE 227 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 213. TABLE 228 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214. TABLE 229 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 214. TABLE 230 LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER 215. TABLE 231 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2023–2031 (USD BILLION) 215. TABLE 232 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 216. TABLE 233 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,. BY COUNTRY, 2023–2031 (USD BILLION) 216. TABLE 234 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217. TABLE 235 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 217. TABLE 236 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218. TABLE 237 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD BILLION) 218. TABLE 238 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2023–2031 (USD BILLION) 219. TABLE 239 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 219. TABLE 240 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,. BY COUNTRY, 2023–2031 (USD BILLION) 220. TABLE 241 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 220. TABLE 242 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221. TABLE 243 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221. TABLE 244 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2031 (USD BILLION) 221. TABLE 245 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD BILLION) 222. TABLE 246 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223. TABLE 247 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 223. TABLE 248 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224. TABLE 249 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 224. TABLE 250 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225. TABLE 251 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 225. TABLE 252 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2031 (USD BILLION) 226. TABLE 253 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 226. TABLE 254 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227. TABLE 255 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 227. TABLE 256 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228. TABLE 257 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228. TABLE 258 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2031 (USD BILLION) 228. TABLE 259 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT,. BY REGION, 2023–2031 (USD BILLION) 229. TABLE 260 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230. TABLE 261 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 230. TABLE 262 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231. TABLE 263 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 231. TABLE 264 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232. TABLE 265 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2031 (USD BILLION) 232. TABLE 266 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2031 (USD BILLION) 233. TABLE 267 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2031 (USD BILLION) 233.
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポートMarketsandMarkets社の Pharmaceuticals分野 での最新刊レポート
本レポートと同じKEY WORD(active pharmaceutical)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|